EULAV Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

EULAV Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-380,000	Closed	-$12.1M	–	207
2022 Q2	$12.1M	Sell	380,000 -45,000	-11%	-$1.32M	0.5%	61
2022 Q1	$14.7M	Sell	425,000 -75,000	-15%	-$2.24M	0.44%	69
2021 Q4	$14.6M	Buy	500,000 +50,000	+11%	+$1.55M	0.37%	81
2021 Q3	$11.5M	Buy	450,000 +40,000	+10%	+$1.18M	0.3%	97
2021 Q2	$14.4M	Buy	410,000 +65,000	+19%	+$2.54M	0.38%	92
2021 Q1	$14.1M	Buy	345,000 +25,000	+8%	+$1.15M	0.38%	89
2020 Q4	$13.9M	Buy	+320,000	New	+$15.8M	0.36%	92

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EULAV Asset Management's GBT Position: Q3 2022 in Review

EULAV Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 380,000 shares — an estimated $12.1M sold.

EULAV Asset Management first reported a position in GBT in Q4 2020 and held it in 7 quarters. The position peaked at $14.7M in Q1 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

EULAV Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
EULAV Asset Management sold 380,000 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $12.1M.
EULAV Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2020 and held it in 7 quarters.
EULAV Asset Management's Global Blood Therapeutics, Inc. position peaked at $14.7M in Q1 2022.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on EULAV Asset Management's 13F filing for Q3 2022, filed 4 Nov 2022.